vs
Side-by-side financial comparison of ABVC BIOPHARMA, INC. (ABVC) and NOVARTIS AG (NVS). Click either name above to swap in a different company.
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $796.0K | — | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | — | ||
| Q2 24 | $117.1K | — | ||
| Q1 24 | $1.2K | — | ||
| Q4 23 | $2.2K | — | ||
| Q3 23 | $15.9K | — | ||
| Q2 23 | $6.1K | — |
| Q3 25 | $-2.0M | — | ||
| Q4 24 | $-731.6K | — | ||
| Q3 24 | $-394.8K | — | ||
| Q2 24 | $-942.3K | — | ||
| Q1 24 | $-2.8M | — | ||
| Q4 23 | $-383.3K | — | ||
| Q3 23 | $-3.3M | — | ||
| Q2 23 | $-2.3M | — |
| Q3 25 | 100.0% | — | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | 77.0% | — | ||
| Q4 23 | -6329.8% | — | ||
| Q3 23 | -86.4% | — | ||
| Q2 23 | -1094.6% | — |
| Q3 25 | -246.8% | — | ||
| Q4 24 | -35837.4% | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | — | ||
| Q1 24 | -235539.8% | — | ||
| Q4 23 | -23641.3% | — | ||
| Q3 23 | -13566.3% | — | ||
| Q2 23 | -35911.6% | — |
| Q3 25 | -256.6% | — | ||
| Q4 24 | -37211.3% | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | — | ||
| Q1 24 | -235203.2% | — | ||
| Q4 23 | -17705.7% | — | ||
| Q3 23 | -20885.9% | — | ||
| Q2 23 | -37052.1% | — |
| Q3 25 | $-0.09 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.29 | — | ||
| Q4 23 | $0.25 | — | ||
| Q3 23 | $-0.82 | — | ||
| Q2 23 | $-0.68 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
